<DOC>
	<DOC>NCT02660229</DOC>
	<brief_summary>The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients taking morphine sulfate versus oxycodone hydrochloride.</brief_summary>
	<brief_title>An Interventional Study for Patients With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through IV Continuous Infusion</brief_title>
	<detailed_description />
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1. Adult men and women aged 19 years or more 2. Patients with cancerous pain who are hospitalized or scheduled for hospitalization at Screening and not planned to be discharged during the study 3. Patients with mean moderate to severe pain over the past 7 days at Screening as verbally confirmed (NRS 4 or higher) 4. Subjects who voluntarily signed the Informed Consent Form for the study 5. Subjects who are capable of understanding details of the study and verbal communication on pain intensity Exlcusion Criteria: 1. Patients who reached the narcotic analgesic dose corresponding to the followings for cancerous pain treatment immediately prior to Screening (oral morphine dose 195mg/day, oral oxycodone dose 130mg/day, patch fentanyl dose 75μg/hour)14) 2. Patients with a medical history of hypersensitivity to an ingredient of oxycodone hydrochloride or morphine sulfate or other narcotic analgesics 3. Patients who have contraindications and cautions when study drugs administered</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Intravenous injection in cancer pain</keyword>
</DOC>